Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BNT 161
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
BNT 161 is a modified quadrivalent mRNA influenza vaccine candidate developed by BioNTech and Pfizer to prevent seasonal influenza by inducing immune responses against influenza A and B strains. It is part of BioNTech/Pfizer’s mRNA vaccine portfolio and has advanced to phase 3 clinical development for influenza, with additional development in a combined COVID‑19 and influenza mRNA vaccine alongside tozinameran (Comirnaty). As an mRNA vaccine, BNT 161 delivers nucleoside‑modified mRNA encoding influenza antigens in lipid nanoparticles to host cells, which then express the antigens and stimulate neutralizing antibody and cellular immune responses.
- Other names
- Quadrivalent influenza modRNA vaccine
Beyond the preview
Go deeper on BNT 161.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BNT 161.